Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
about
Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literatureDocetaxel does not impair skeletal muscle force production in a murine model of cancer chemotherapyDigital image analysis of HER2 immunohistochemistry in gastric- and oesophageal adenocarcinoma: a validation study on biopsies and surgical specimens.Angiogenesis inhibitors in early development for gastric cancer.Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study.Chromosomal breaks at FRA18C: association with reduced DOK6 expression, altered oncogenic signaling and increased gastric cancer survival.A systematic review and meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer
P2860
Q26741242-61ABEDCF-25AE-4276-B045-5CD95A0ACEDDQ33800180-666EEBD6-0383-4003-823D-931DD037958DQ40107322-567B79E8-E009-4309-9EDB-E360A116EC6BQ47996955-F5A7A890-1C5A-433B-933C-6AAC025BCA21Q52880999-7A1B56B1-6431-4042-9AEA-1A679C85C577Q53621686-9CA29310-A2E0-4384-B296-6D851BF05FC4Q54109361-1BEBF1C2-526F-4BF6-958D-0029B86F7B1EQ54976924-80AB0A9C-DC88-406A-B45D-D5DA298AF820Q58547850-A0ED31EC-B65B-4F2C-A387-6D0CFFD94757
P2860
Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Trastuzumab and bevacizumab co ...... a multicenter phase II study.
@en
Trastuzumab and bevacizumab co ...... a multicenter phase II study.
@nl
type
label
Trastuzumab and bevacizumab co ...... a multicenter phase II study.
@en
Trastuzumab and bevacizumab co ...... a multicenter phase II study.
@nl
prefLabel
Trastuzumab and bevacizumab co ...... a multicenter phase II study.
@en
Trastuzumab and bevacizumab co ...... a multicenter phase II study.
@nl
P2093
P2860
P1476
Trastuzumab and bevacizumab co ...... a multicenter phase II study.
@en
P2093
Aart Beeker
Annemieke Cats
Didier Meulendijks
James E Boers
Jan H M Schellens
Jan Willem B de Groot
Johanna E A Portielje
Jos H Beijnen
Karolina Sikorska
P2860
P2888
P304
P356
10.1007/S10637-015-0309-4
P577
2015-12-08T00:00:00Z